Wave Life Sciences WVE 深 滬
等待開盤 08-01 09:30:00 美东时间
5.525
-0.235
-4.08%
華盛通- 最 高5.74
- 今 開5.70
- 成交量 127.50万股
- 最 低 5.37
- 昨 收 5.76
- 總市值 10.63亿
- 52周最高 21.73
- 市盈率 靜 --
- 換手率 0.66%
- 52周最低 5.02
- 委 比 10.61%
- 總股本 1.92亿
- 歷史最高 56.00
- 量 比 1.15
- 振 幅 6.42%
- 歷史最低 1.16
- 每 手 1
- 風險率 3.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Wedbush Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $12
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $15 to $12.
07-31 21:02
Wave Life Sciences posts Q2 results, pipeline update
The latest announcement is out from Wave Life Sciences ( ($WVE) ). Wave Life Sc...
07-30 19:57
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
Wave Life Sciences Ltd. has received shareholder approval for its proposed redomiciliation to the United States, subject to Singapore High Court approval. The company has filed an application for the Scheme of Arrangement, scheduled for a court hearing on July 14, 2026. Wave, a biotech company focused on RNA medicines, aims to unlock the potential of RNA therapies for various diseases. The company emphasizes its PRISM® platform and pipeline progr...
07-07 20:15
Wave Life Sciences Shareholders Approve Redomiciliation Scheme
An update from Wave Life Sciences ( ($WVE) ) is now available. On June 22, 2026...
06-26 20:59
Wave Life Sciences Initiates Phase 2a Multidose Portion Of INLIGHT Trial, Placebo-Controlled Study Evaluating WVE-007 As Monotherapy In Individuals Living With Obesity With High BMI And Comorbidities
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing Phase 2a portion in individuals with higher BMI and body fat, with and without type 2 diabetes, includes...
06-24 20:31
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
Wave Life Sciences Announces Updated Data From Ongoing RestorAATion-2 Trial Of WVE-006, Investigational, GalNAc-Conjugated, Subcutaneously Delivered RNA Editing Oligonucleotide For Alpha-1 Antitrypsin Deficiency
Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing On
05-19 04:32
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
美股大行评级 | 苹果获多家机构上调目标价，最高至335美元；闪迪获华尔街大行看多至2000美元
今日重点评级关注：Benchmark：维持史密斯微软件"买入"评级，目标价从2美元升至2.5美元；Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元
05-04 16:04
